A 28-year-old woman with lepromatous leprosy is started on standard multidrug therapy including rifampicin, dapsone, and clofazimine. Which is the most common cutaneous manifestation of clofazimine toxicity during long-term therapy?

Explanation

## Clofazimine Cutaneous Toxicity **Key Point:** Blue-black or brown discoloration of the skin is the most common and characteristic cutaneous adverse effect of clofazimine, occurring in nearly 75–100% of patients on prolonged therapy. ### Mechanism of Pigmentation Clofazimine is a lipophilic dye that: 1. **Accumulates in fatty tissues** — including subcutaneous fat and sebaceous glands 2. **Deposits in melanin-rich areas** — particularly the stratum corneum and dermis 3. **Produces a blue-black discoloration** — visible within 2–4 weeks of therapy; intensity increases over months 4. **Persists long after discontinuation** — may take 6–12 months to fade completely due to slow tissue clearance ### Clinical Presentation - **Onset:** 2–4 weeks after starting clofazimine - **Distribution:** generalized, but more prominent in sun-exposed areas and areas of pre-existing inflammation - **Appearance:** blue-black, brown, or slate-gray discoloration - **Associated features:** ichthyosis, dryness, follicular hyperkeratosis (but discoloration is the primary finding) - **Reversibility:** slowly fades over 6–12 months after stopping the drug ### Why This Occurs So Frequently **High-Yield:** Clofazimine is a lipophilic antimycobacterial agent with intrinsic pigmentation. Accumulation in skin lipids is inevitable and universal with prolonged use. ### Comparison of Clofazimine Toxicities | Adverse Effect | Frequency | Onset | Reversibility | Clinical Significance | |---|---|---|---|---| | Blue-black skin discoloration | 75–100% | 2–4 weeks | Slow (6–12 months) | Cosmetic concern; not dangerous | | Ichthyosis/dry skin | 30–50% | Variable | Reversible | Mild; manageable with emollients | | GI disturbances (abdominal pain, diarrhea) | 10–30% | Variable | Reversible | Can be dose-limiting | | Hepatotoxicity | Rare (<1%) | Variable | Reversible | Uncommon; monitor LFTs | | Erythema nodosum leprosum (ENL) | 10% (Type 2 reaction) | Months into therapy | Reversible | Immune-mediated; not direct toxicity | **Clinical Pearl:** Warn patients about skin discoloration **before** starting clofazimine. Reassure them it is cosmetic, reversible, and not a sign of toxicity. This improves adherence. **Mnemonic:** CLOFAZIMINE = **C**olor **L**ipophilic **O**ccurs **F**requently **A**ccumulates **Z**ealously **I**n **M**elanin-rich **I**ntegument **N**ot **E**xpressed **S**wiftly (post-cessation) ### Distinction from Erythema Nodosum Leprosum (ENL) **Warning:** Do not confuse clofazimine pigmentation (a direct drug effect) with ENL (a Type 2 immune reaction). ENL presents with painful nodules, fever, and systemic symptoms; clofazimine discoloration is asymptomatic and cosmetic. [cite:KD Tripathi 8e Ch 47]